Celcuity (NASDAQ:CELC) Lifted to “Strong-Buy” at Leerink Partnrs

Leerink Partnrs upgraded shares of Celcuity (NASDAQ:CELC) to a strong-buy rating in a research report released on Monday morning, Zacks.com reports. Leerink Partnrs also issued estimates for Celcuity’s Q2 2024 earnings at ($0.72) EPS, Q3 2024 earnings at ($0.77) EPS, Q4 2024 earnings at ($0.74) EPS, FY2024 earnings at ($2.88) EPS, FY2025 earnings at ($3.43) EPS, FY2026 earnings at ($2.61) EPS and FY2027 earnings at $1.16 EPS.

A number of other research analysts also recently weighed in on the stock. Needham & Company LLC decreased their price objective on shares of Celcuity from $24.00 to $23.00 and set a buy rating for the company in a research report on Friday, May 31st. Craig Hallum reiterated a buy rating and set a $27.00 price target (up previously from $25.00) on shares of Celcuity in a research report on Thursday, May 16th. Stifel Nicolaus restated a buy rating and issued a $40.00 price objective on shares of Celcuity in a research report on Thursday, May 16th. SVB Leerink began coverage on Celcuity in a research report on Monday. They set an outperform rating and a $29.00 target price on the stock. Finally, HC Wainwright restated a buy rating and set a $27.00 price objective on shares of Celcuity in a research report on Thursday, May 16th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of Buy and a consensus price target of $29.20.

Celcuity Stock Up 2.5 %

Celcuity stock opened at $19.15 on Monday. Celcuity has a 52 week low of $8.39 and a 52 week high of $22.19. The firm has a market cap of $672.17 million, a price-to-earnings ratio of -6.89 and a beta of 0.81. The business’s 50-day moving average price is $16.21 and its 200 day moving average price is $16.55. The company has a quick ratio of 11.23, a current ratio of 11.23 and a debt-to-equity ratio of 0.28.

Celcuity (NASDAQ:CELC) last issued its quarterly earnings data on Wednesday, May 15th. The company reported ($0.64) EPS for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.07. As a group, sell-side analysts anticipate that Celcuity will post -2.85 earnings per share for the current year.

Institutional Trading of Celcuity

Large investors have recently made changes to their positions in the company. Perceptive Advisors LLC acquired a new stake in Celcuity during the 4th quarter worth $21,583,000. Commodore Capital LP grew its stake in Celcuity by 3.6% during the 4th quarter. Commodore Capital LP now owns 1,754,704 shares of the company’s stock valued at $25,566,000 after acquiring an additional 60,563 shares in the last quarter. Trust Point Inc. purchased a new stake in Celcuity during the 4th quarter valued at about $297,000. Pale Fire Capital SE raised its holdings in Celcuity by 38.4% in the 4th quarter. Pale Fire Capital SE now owns 14,409 shares of the company’s stock valued at $210,000 after acquiring an additional 4,000 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new position in Celcuity in the 4th quarter worth approximately $139,000. 63.33% of the stock is currently owned by hedge funds and other institutional investors.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.